In the Spotlight...

Cis interactions between CD2 and its ligands on T cells are required for T cell activation

Li et al. generated CD2 or CD48 (murine CD2 ligand) KO mice and tagged-CD2 knockin mice. CD2 KO or Ab blockade, or CD48 KO blunted in vitro TCR-stimulated T cell responses in the presence or absence o...

Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Cichocki et al. generated human iPSC-derived NK cells expressing a CD19-CAR containing the NKG2D, 2B4, and CD3ζ signaling domains, a high-affinity, non-cleavable CD16 shown to enhance therapeutic Ab-d...

Size-dependent activation of CAR-T cells

Xiao et al. tested how CAR T cell activation is affected by the relative lengths of the CAR construct, the antigen target, and the membrane phosphatase CD45. Reducing the length of the CAR extracellul...

Transcriptomic diversity in human medullary thymic epithelial cells

Carter et al. combined high-throughput 5’Cap sequencing with standard RNA sequencing to investigate gene expression and transcript diversity in immature (MHC-IIlo) and mature (MHC-IIhi) human mTECs, a...

Previous Digests

Targeting tumor defenses to enhance immunotherapy

August 10, 2022

In cancer immunotherapy, research is often focused on improving the immune attack against cancer. However, Kishton and Patel et al. recently turned their attention towards how cancer defends itself against immune attacks, and how these defense mechanisms could potentially...

PD-1-high TILs: a predictive biomarker for ICB in lung cancer

August 3, 2022

Despite the promise of immune checkpoint blockade (ICB) therapy in treating non-small cell lung cancer (NSCLC), the majority of patients do not respond and toxicity remains a major issue. Identifying biomarkers of ICB efficacy could direct treatment to responsive...

Enhancing ACT with o9R

July 27, 2022

Adoptive T cell therapy has come a long way in recent years, but it typically requires lymphodepleting pre-treatment, which can limit patient eligibility, and its efficacy is still limited in many patients. In recent efforts to improve ACT, particularly...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Samuel (Sandy) Goldman

Samuel (Sandy) Goldman

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Elaine Yee Lin Chung

Elaine Yee Lin Chung

Nathan Suek

Nathan Suek

Margot O'Toole

Margot O'Toole

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.